Jean-marc A. Nabholtz, MD

home / authors / jean-marc-nabholtz-md

Articles

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

Jean-marc A. Nabholtz, MD;Michael Smylie, MD;John R. Mackey, MD;Dick Au, MD;Evelyn Sansregret, MD;Daniel Noel, MD;Alexander H. Paterson, MD;Taher Al-tweigeri, MD;Fernad Delorme, MD;Allesandro Riva, MD

August 1st 1997

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

Jean-marc A. Nabholtz, MD;B. Thuerlimann, MD;W. R. Bezwoda, MD;D. Melnychuk, MD;L. Deschênes, MD;J. Douma, MD;T. A. Vandenberg, MD;B. Rapoport, MD;R. Rosso, MD;V. Trillet-lenoir, MD;J. Drbal, MD;Matti S. Aapro, MD;M. Alaki, MD;M. Murawsky, MD;Allesandro Riva, MD

August 1st 1997

This nonblinded, multicenter, randomized phase III study compares the median time to progression (primary endpoint), response rate, and quality of life, safety, and survival of

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastic Breast Cancer

Jean-marc A. Nabholtz, MD;John R. Mackey, MD;Alexander Paterson, MD;Daniel Noel, MD;Taher Al-tweigeri, MD;Anna Janowska, MD;Fe Delorme, MD;Alexander Riva, MD

June 1st 1997

A pilot phase II study examined the feasibility of 75 mg/m² of docetaxel (Taxotere) in combination with 50 mg/m²of doxorubicin and 500 mg/m² of cyclophosphamide (Cytoxan, Neosar) in the first-line treatment of metastatic breast cancer. This study was designed to evaluate the efficacy and toxicity of the docetaxel/doxorubicin/cyclophosphamide combination both alone and as induction before high-dose chemotherapy, supplemented by autologous peripheral blood stem-cell transplantation.